Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

67.68 +0.70 (+1.05%)
Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
34 35 Next >
Expert Ratings for Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
5 Analysts Have This to Say About Bristol-Myers Squibb
Analysts have provided the following ratings for Bristol-Myers Squibb (NYSE:BMY) within the last quarter: 
Via Benzinga
This Is What Whales Are Betting On Bristol-Myers Squibb
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65. 
Via Benzinga
QSR Stock Pops as Burger Kings Announces $400 Million Investment
Restaurant Brands International (QSR) stock is gaining on Monday after Burger King announced plans to invest $400 million into its business. 
Via InvestorPlace
Adobe (ADBE) Stock Slips on Analyst Downgrade
Adobe (ADBE) stock is sliding lower on Monday after the software company was hit with a downgrade from Mizuho analyst Gregg Moskowitz. 
Via InvestorPlace
Bristol-Myers Squibb (BMY) Stock Jumps 8% as FDA Approves Psoriasis Treatment
Bristol-Myers Squibb is going after Amgen's $2 billion a year Otezla franchise with Sotyktu. BMY stock is up on the news. 
Via InvestorPlace
Here's Why Amgen Shares Are Diving
Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 4.11% to $237.51 during Monday's pre-market session following FDA approval of Bristol Myers Squibb Co's (NYSE: BMY) plaque psoriasis drug Sotyktu,... 
Via Benzinga
HC Wainwright Cuts Price Target On This Stock By 73%, Also Check Out Other Major PT Changes Here
Susquehanna cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $195. Susquehanna analyst Shyam Patil maintained the stock with a Positive rating. Baidu shares rose 0.7% to $139.38 in... 
Via Benzinga
Bristol-Myers Squibb, Carvana And Some Other Big Stocks Recording Gains In Today's Pre-Market Session
U.S. stock futures traded higher this morning after recording gains in the previous session. Here are some big stocks moving higher in today’s pre-market trading session. 
Via Benzinga
Bristol-Myers Squibb To $87? Here Are 5 Other Price Target Changes For Monday
Atlantic Equities raised the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $83 to $87. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock.... 
Via Benzinga
Why Clovis Oncology Is Trading Higher By 14%; Here Are 28 Stocks Moving Premarket
Gainers Aditxt, Inc. (NASDAQ: ADTX) rose 46.1% to $0.2801 in pre-market trading after jumping 37% on Friday. 
Via Benzinga
Bristol Myers' Deucravacitinib Scores FDA Approval For Plaque Psoriasis
 
Via Benzinga
Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
From Bristol Myers Squibb
Via Business Wire
5 Stocks That Michael Burry Just Dumped From His Portfolio
Now holding just one stock in his portfolio, contrarian investor Michael Burry has cashed out of these five stocks. 
Via InvestorPlace
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
Bristol Myers Squibb to Participate in Citi’s 17th Annual BioPharma Conference
From Bristol Myers Squibb
Via Business Wire
S&P 500 Stock Market Winners Today
Diamondback Energy was the index's top performer Monday. 
Via Investor's Business Daily
Why Bristol-Myers Squibb Stock Fell Today
Bristol-Myers Squibb Co (NYSE: BMY) shares traded lower Monday after the company announced, in collaboration with Janssen Pharmaceuticals, that the results from the Phase 2 AXIOMATIC-SSP dose-ranging... 
Via Benzinga
Looking Into Bristol-Myers Squibb's Recent Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 14.5% since its last report. The company recently reported that it has 23.84 million shares sold short,... 
Via Benzinga
Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops
The companies hoped to reduce the risk of myriad complications for at-risk patients. 
Via Investor's Business Daily
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
Bristol Myers-JNJ Partnered Secondary Stroke Drug Misses Endpoint, But Companies See Enough Potential For Phase 3 Trials
 
Via Benzinga
Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy
From Bristol Myers Squibb
Via Business Wire
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.